A warning from U.S. regulators linking GlaxoSmithKline Plc’s diabetes drug Avandia to rare cases of swelling in the back of the eye is unlikely to have a major impact on sales, analysts said on Friday.
The Food and Drug Administration highlighted the problem in a notice late on Thursday after the drug maker said it had received “very rare” reports of the swelling, known as macular oedema, in patients taking Avandia.
The warning also applies to Avandamet, a combination product containing the same active ingredient, and Avandaryl, which will be available later in January.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.